Bio-Rad Laboratories Inc. Class A

350.39-1.16-0.33%Vol 112.17K1Y Perf -17.83%
Oct 3rd, 2023 15:59 DELAYED
BID350.33 ASK350.78
Open348.74 Previous Close351.55
Pre-Market351.55 After-Market-
 - -%  - -
Target Price
621.67 
Analyst Rating
Strong Buy 1.25
Potential %
76.99 
Finscreener Ranking
★★★★+     56.00
Insiders Trans % 3/6/12 mo.
-/-/-100 
Value Ranking
★★★+     52.34
Insiders Value % 3/6/12 mo.
-/-/-100 
Growth Ranking
★★     45.15
Insiders Shares Cnt. % 3/6/12 mo.
-/-/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
3.49 
Earnings Rating
Strong Sell
Market Cap10.19B 
Earnings Date
26th Oct 2023
Alpha0.00 Standard Deviation0.10
Beta0.89 

Today's Price Range

347.24352.87

52W Range

344.63509.62

5 Year PE Ratio Range

4.30288.30

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
0.37%
1 Month
-10.91%
3 Months
-6.89%
6 Months
-24.37%
1 Year
-17.83%
3 Years
-31.16%
5 Years
14.81%
10 Years
198.48%

TickerPriceChg.Chg.%
BIO350.39-1.1600-0.33
AAPL172.38-1.3700-0.79
GOOG133.17-2.0000-1.48
MSFT313.25-8.5500-2.66
XOM115.770.14000.12
WFC38.66-0.9500-2.40
JNJ155.290.14000.09
FB196.640.99000.51
GE107.63-1.1600-1.07
JPM142.70-1.0700-0.74
Financial StrengthValueIndustryS&P 500US Markets
4.00
5.50
0.12
0.14
-291.60
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
56.10
-278.60
-273.90
-3.40
-69.91
RevenueValueIndustryS&P 500US Markets
2.07B
83.72
8.24
6.41
Earnings HistoryEstimateReportedSurprise %
Q02 20232.553.0017.65
Q01 20233.243.343.09
Q04 20223.453.31-4.06
Q03 20222.592.600.39
Q02 20222.463.3837.40
Q01 20222.804.9476.43
Q04 20212.873.2111.85
Q03 20212.303.7161.30
Earnings Per EndEstimateRevision %Trend
9/2023 QR2.87-18.00Negative
12/2023 QR3.71-15.49Negative
12/2023 FY12.93-6.44Negative
12/2024 FY14.78-8.43Negative
Next Report Date26th Oct 2023
Estimated EPS Next Report2.87
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume112.17K
Shares Outstanding29.08K
Shares Float20.54M
Trades Count6.79K
Dollar Volume39.30M
Avg. Volume154.43K
Avg. Weekly Volume115.16K
Avg. Monthly Volume168.49K
Avg. Quarterly Volume179.64K

Bio-Rad Laboratories Inc. Class A (NYSE: BIO) stock closed at 351.55 per share at the end of the most recent trading day (a -1.92% change compared to the prior day closing price) with a volume of 123.37K shares and market capitalization of 10.19B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 8000 people. Bio-Rad Laboratories Inc. Class A CEO is Norman Schwartz.

The one-year performance of Bio-Rad Laboratories Inc. Class A stock is -17.83%, while year-to-date (YTD) performance is -16.4%. BIO stock has a five-year performance of 14.81%. Its 52-week range is between 344.63 and 509.6225, which gives BIO stock a 52-week price range ratio of 3.49%

Bio-Rad Laboratories Inc. Class A currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 1.48, a price-to-sale (PS) ratio of 5.09, a price to cashflow ratio of 47.80, a PEG ratio of 0.40, a ROA of -41.67%, a ROC of -47.65% and a ROE of -56.29%. The company’s profit margin is -69.91%, its EBITDA margin is -273.90%, and its revenue ttm is $2.07 Billion , which makes it $83.72 revenue per share.

Of the last four earnings reports from Bio-Rad Laboratories Inc. Class A, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.87 for the next earnings report. Bio-Rad Laboratories Inc. Class A’s next earnings report date is 26th Oct 2023.

The consensus rating of Wall Street analysts for Bio-Rad Laboratories Inc. Class A is Strong Buy (1.25), with a target price of $621.67, which is +76.99% compared to the current price. The earnings rating for Bio-Rad Laboratories Inc. Class A stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Bio-Rad Laboratories Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Bio-Rad Laboratories Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 9.51, ATR14 : 8.85, CCI20 : -93.78, Chaikin Money Flow : -0.19, MACD : -8.30, Money Flow Index : 61.01, ROC : -5.82, RSI : 36.62, STOCH (14,3) : 12.18, STOCH RSI : 0.47, UO : 40.93, Williams %R : -87.82), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Bio-Rad Laboratories Inc. Class A in the last 12-months were: Ajit Ramalingam (Sold 0 shares of value $0 ), Ajit Ramalingam (Sold 396 shares of value $166 315 ), Crowley Michael (Sold 500 shares of value $189 695 ), Dara Wright (Option Excercise at a value of $0), Daskal Ilan (Sold 0 shares of value $0 ), Ernst Timothy (Option Excercise at a value of $167 819), Ernst Timothy (Sold 1 746 shares of value $849 300 ), Ilan Daskal (Option Excercise at a value of $0), Last Andrew (Sold 0 shares of value $0 ), Timothy S. Ernst (Option Excercise at a value of $167 819), Timothy S. Ernst (Sold 1 746 shares of value $849 300 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.25
Strong Buy
1.25

Bio-Rad Laboratories Inc. Class A

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (60% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the United States (40% of 2020 sales), Europe (34%), and Asia (21%), with Canada and Latin America accounting for the bulk of the remaining 5%. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

CEO: Norman Schwartz

Telephone: +1 510 724-7000

Address: 1000 Alfred Nobel Drive, Hercules 94547, CA, US

Number of employees: 8 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

55%45%

Bearish Bullish

55%45%

 

TipRanks News for BIO

Wed, 30 Aug 2023 01:45 GMT Bio-Rad Laboratories (BIO) Receives a Buy from RBC Capital

- TipRanks. All rights reserved.

News

Stocktwits